- Joined
- 8 June 2014
- Posts
- 29
- Reactions
- 0
Apologies for the delay in response, especially given how very helpful your experience has been. Have not reviewed in detail. Initial observations on surface read:
Market pleasantly surprised by evidence of reversion to long term ARS growth rate. Has been tracking unreasonably low since IPO.
Clearly responding positively to expectations for FY16 reported NPAT to be +25% although revisions to expectations did not come though. FactSet is tracking 6 analysts. One revised up, one down and average didn't do anything. Analysts are not giving credence to the stated outlook. Possible upside surprise and credibility restoration if the target can be hit.
There are significant margin pressures in KL.
Low intervention is lower margin off lower revenue. Will eventually bite into main line offering. What rate of revenue and EBITDA compression will occur?
Beginning to grow further away from core IVF by moving to complementary services (day care hospitals, SUFW) and having to engage in pre-emptive self cannibalisation (Bump, MyIVF).
Fair chunk of headline growth is via acquisition. Need to check pricing achieved and hence price for growth.
Suspect that increasing supply of IVF specialists offers upside via increasing share of revenue retained.
Lots of questions unanswered at this time. Just first impressions.
Cheers